Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A)Symptoms, Doctors, Treatments, Advances & More
Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A) Overview
Learn About Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Frits Wijburg practices practicing medicine in Amsterdam, Netherlands. Wijburg is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A). They are also highly rated in 16 other conditions, according to our data. Their clinical expertise encompasses Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A), Mucopolysaccharidoses (MPS), Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, and Bone Marrow Transplant.
Fairview Express Care
Chester Whitley is a Pediatrics specialist and a Medical Genetics provider practicing medicine in Minneapolis, Minnesota. Dr. Whitley is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A). He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A), and Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome). Dr. Whitley is currently accepting new patients.
Stuart Ellison practices practicing medicine in Manchester, United Kingdom. Mr. Ellison is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A). He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), Mucopolysaccharidoses (MPS), and Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome).
Summary: The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).